Original ArticlesA Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
Key Words
Cited by (0)
Disclosure: The consensus meeting was funded by unrestricted educational grants from Eli Lilly, AstraZeneca, Hoffman La Roche, Amgen, Pfizer, Abraxis Biosciences, and Boehringer Ingelheim.
Meeting attendees in addition to the authors: Gwyn Bebb, Calgary, AB; Nicole Bouchard, Sherbrooke, QC; Guilherme Brandao, Montreal, QC; Ron Burkes, Toronto, ON; Charles Butts, Edmonton, AB; George Chong, Montreal, QC; Quincy Chu, Edmonton, AB; Victor Cohen, Montreal, QC; Daniel Dion, Montreal, QC; John Goffin, Hamilton, ON; Marcio Gomes, Ottawa, ON; Glen Goss, Ottawa, ON; Gary Harding, Winnipeg, MB; Vera Hirsh, Montreal, QC; Suzanne Kamel-Reid, Toronto, ON; Christopher Lee, Fraser Valley, BC; Mary Macneil, Halifax, NS; Tony Magliocco, Edmonton, AB; Don Morris, Edmonton, AB; Stewart Rorke, St. Johns, NF; Harman Sekon, Ottawa, ON; Mark Vincent, London, ON; Lydia Vincic, Hamilton, ON; Renaud Whittom, Montreal, QC; Zhaolin Xu, Halifax, NS; Sunil Yadav, Saskatoon, SK.